Cost comparison model of a novel treatment for venous thromboembolism
Development of a flexible and interactive model for Japan
Our client was planning the launch of a novel treatment for venous thromboembolism (VTE) in Japan. The treatment had previously been clinically and economically studied in the US, however due to the unique nature of the Japanese market our client wished to perform a costing analysis specific to this market.
The client provided evidence from a separate study which had been conducted in Japan, including data on detailed healthcare resource utilisation from length of hospital stay to the number of unscheduled tests for each patient.
We developed an interactive cost-comparison model which compared per-patient costs associated with the new treatment to the current standard of care. The model was fully interactive and allowed users to vary:
- The proportion of patients with deep vein thrombosis/pulmonary embolism.
- The distribution of treatment lengths.
- The costs associated with each resource.
This flexibility allowed the user to analyse the data by exploring alternative scenarios, indirect costs and reflecting differences in local practices.
Through the different scenarios, our client was able to see where their new treatment would be cost effective. For example, when the majority of patients received treatment for a short duration (three months), the new treatment was more cost effective compared to the standard of care.
Japan is a unique market because of the low cost of a hospital stay – other markets, such as the US and UK, have higher associated costs.
Value to the client
This model allowed the client to appreciate the challenges and opportunities of launching their product in Japan, which enabled them to plan accordingly.